Results 71 to 80 of about 9,102 (179)

Association between CYP2B6 genetic variability and cyclophosphamide therapy in pediatric patients with neuroblastoma

Scientific Reports, 2023
Cyclophosphamide, an oxazaphosphorine prodrug is frequently used in treatment of neuroblastoma, which is one of the most prevalent solid organ malignancies in infants and young children.
Katalin Mangó, Ferenc Fekete, Ádám Ferenc Kiss, Réka Erdős, János Tibor Fekete, Tamás Bűdi, Edit Bruckner, Miklós Garami, Tamás Micsik, Katalin Monostory   +9 more
doaj   +1 more source

Advances in New Approach Methodologies at FDA's Division of Applied Regulatory Science

Clinical Pharmacology &Therapeutics, Volume 120, Issue 5, Page 1250-1254, November 2026.
New Approach Methodologies (NAMs) represent a paradigm shift in drug development and regulatory science, offering human‐relevant alternatives to traditional preclinical models. This mini‐review highlights recent advances in NAM development, validation, and regulatory application from FDA's Division of Applied Regulatory Science (DARS).
Ksenia Blinova, Kimberly Chiu, Anik Chaturbedi, Jahan Cooper, Tromondae K. Feaster, Paula L. Hyland, Lidiya Stavitskaya, Wendy W. Wu, Jeffry Florian, Rodney Rouse   +9 more
wiley   +1 more source

Association of CYP2B6 Genetic Variation with Efavirenz and Nevirapine Drug Resistance in HIV-1 Patients from Botswana

Pharmacogenomics and Personalized Medicine, 2021
Monkgomotsi J Maseng,1,2 Leabaneng Tawe,1– 3 Prisca K Thami,2,4 Kaelo K Seatla,1,2 Sikhulile Moyo,2,5 Axel Martinelli,6 Ishmael Kasvosve,1 Vladimir Novitsky,2,5 Max Essex,2,5 Gianluca Russo,7 Simani Gaseitsiwe,2,5 Giacomo M Paganotti3,8,9 1School ...
Maseng MJ, Tawe L, Thami PK, Seatla KK, Moyo S, Martinelli A, Kasvosve I, Novitsky V, Essex M, Russo G, Gaseitsiwe S, Paganotti GM   +11 more
doaj  

Identifying Dose‐Relevant Covariates With SCOUT: A Case Study of Lorlatinib

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 11, November 2026.
ABSTRACT Molecularly targeted therapeutics, such as lorlatinib, are typically initiated at fixed starting doses with subsequent tolerability‐guided modifications, although substantial interindividual variability in pharmacokinetics and drug exposure may influence both efficacy and safety outcomes.
Yasuhisa Ideno
wiley   +1 more source

Inhibition of CYP2B6 by Medicinal Plant Extracts: Implication for Use of Efavirenz and Nevirapine-Based Highly Active Anti-Retroviral Therapy (HAART) in Resource-Limited Settings

Molecules, 2016
Highly active antiretroviral therapy (HAART) has greatly improved health parameters of HIV infected individuals. However, there are several challenges associated with the chronic nature of HAART administration.
Nicholas E. Thomford, Charles Awortwe, Kevin Dzobo, Faustina Adu, Denis Chopera, Ambroise Wonkam, Michelle Skelton, Dee Blackhurst, Collet Dandara   +8 more
doaj   +1 more source

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

British Journal of Pharmacology, Volume 183, Issue 21, Page 6261-6290, November 2026.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source

Snus, nicotine pouches and cardiovascular disease: Evidence, mechanisms, and the challenge of novel nicotine products

Journal of Internal Medicine, Volume 300, Issue 5, Page 541-552, November 2026.
Abstract Conventional Swedish snus is used by millions in Scandinavia and increasingly worldwide, yet its cardiovascular effects remain poorly characterized. The emergence of nicotine pouches—commonly referred to as ‘white snus’ in Sweden—that deliver comparable nicotine without tobacco constituents adds complexity to a heterogeneous landscape and ...
Magnus Olsson, Hanne Tønnesen, Jakob Hedberg, Johan Sundström, Eva Nordendahl, Björn Klinge, Michael Fored, Cecilia Magnusson, Daniel Jönsson, Peter Persson, Aron Naimi‐Akbar   +10 more
wiley   +1 more source

The Influence of CYP2B6 Variants and Administration of Propofol on Patient Outcomes after Traumatic Brain Injury

Neurotrauma Reports
Management of severe traumatic brain injury (sTBI) typically involves the use of sedation, which inherently results in benefits and risks. The cytochrome P450 enzyme CYP2B6 is involved in the biotransformation of particular drug classes, including many ...
Katherine O’Meara, Ava M. Puccio, Dianxu Ren, Sandra Deslouches, Ruchira Jha, David O. Okonkwo, Yvette P. Conley   +6 more
doaj   +1 more source

Effects of monocyte chemoattractant protein‐1, macrophage inflammatory protein‐1α, and interferon‐α2a on P450 enzymes in human hepatocytes in vitro

Pharmacology Research & Perspectives, 2019
Some immunomodulatory agents stimulate the release of cytokines capable of suppressing P450 enzymes and potentially affecting pharmacokinetics of coadministered medications. Cytokines released in response to an immunomodulator in the blood ex vivo can be
Maciej Czerwiński, Krystal Gilligan, Kevin Westland, Brian W. Ogilvie   +3 more
doaj   +1 more source

Human CYP2B6 produces oxylipins from polyunsaturated fatty acids and reduces diet-induced obesity

PLoS ONE, 2022
Multiple factors in addition to over consumption lead to obesity and non-alcoholic fatty liver disease (NAFLD) in the United States and worldwide. CYP2B6 is the only human detoxification CYP whose loss is associated with obesity, and Cyp2b-null mice show
Melissa M. Heintz, Jazmine A. Eccles, Emily M. Olack, Kristal M. Maner-Smith, Eric A. Ortlund, William S. Baldwin   +5 more
doaj